시장보고서
상품코드
1272050

세계의 핵의학/방사성 의약품 시장 : 유형별(진단용, 치료용), 용도별, 시술별, 최종 사용자별, 지역별 예측(-2028년)

Nuclear Medicine Market / Radiopharmaceuticals Market by Type (Diagnostic, Therapeutic, Application, Procedures, End User - Global Forecast to 2028

발행일: | 리서치사: MarketsandMarkets | 페이지 정보: 영문 342 Pages | 배송안내 : 즉시배송

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 핵의학 시장 규모는 2023년 55억 달러에서 2028년까지 94억 달러에 달할 것으로 예상되며, 예측 기간 동안 11.3%의 CAGR을 나타낼 것으로 예상됩니다.

핵의학 시장의 성장은 주로 CVD의 유병률 증가, 의료 개선을 위한 정부의 이니셔티브, 노인 인구의 급증, PET 및 SPECT 기술의 채택 확대 등의 요인에 기인합니다. 그러나 방사성 의약품의 반감기가 짧기 때문에 잠재적인 채택률이 감소하여 시장 성장을 어느 정도 방해할 것으로 예상됩니다.

예측 기간 동안 치료 부문이 가장 높은 CAGR로 성장할 것으로 예상됩니다.

핵의학 시장은 유형별로 진단용과 치료용으로 분류됩니다. 치료용 부문은 예측 기간 동안 가장 높은 CAGR로 성장할 것으로 예상됩니다. 이는 수술이나 화학요법과 달리 부작용이 적은 동위원소가 종양학에 적용되고 있기 때문으로 추정됩니다.

최종 사용자별로는 병원 부문이 핵의학 시장에서 가장 큰 점유율을 차지할 것으로 예상됩니다.

최종 사용자별로 핵의학 시장은 병원, 이미징 센터, 학술 및 연구센터, 기타(제약/생명공학 기업, 임상시험수탁기관(CRO) 포함)로 구분되며, 2023년 병원 부문은 환자 치료의 질을 향상시키기 위해 방사선과 환자 워크플로우의 자동화 및 디지털화에 대한 관심이 높아지면서 가장 큰 점유율을 차지할 것으로 예상됩니다. 환자 치료의 질을 향상시키기 위해 방사선과 환자의 워크플로우 자동화와 디지털화에 대한 관심이 높아지면서 핵의학 시장에서 가장 큰 점유율을 차지할 것으로 예상됩니다.

지역별로는 북미가 핵의학 시장에서 가장 큰 점유율을 차지할 것으로 예상됩니다.

지역별로는 북미가 2023년 핵의학 시장에서 가장 큰 점유율을 차지할 것으로 예상됩니다. 만성 질환의 유병률 증가로 인해 이 지역의 진단 및 치료 횟수가 증가할 것으로 예상되며, 정부의 재정 지원, 기업의 노력 등이 그 요인으로 작용할 것으로 보입니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 프리미엄 인사이트

제5장 시장 개요

  • 서론
  • 시장 역학
    • 성장 촉진요인
    • 성장 억제요인
    • 기회
    • 과제
  • 밸류체인 분석
  • 에코시스템 범위
  • 규제 상황
  • Porter의 Five Forces 분석
  • 파이프라인 분석
  • 특허 분석
  • 업계 동향
  • 가격 분석
  • 주요 컨퍼런스 및 이벤트(2023년-2024년)
  • 주요 이해관계자와 구입 기준

제6장 핵의학 시장 : 유형별

  • 서론
  • 진단용
    • SPECT
    • PET
  • 치료용
    • 알파 이미터
    • 베타 이미터
    • 근접치료 동위원소

제7장 핵의학 시장 : 용도별

  • 서론
  • 진단용
    • SPECT
    • PET
  • 치료용
    • 갑상선 적응증
    • 골전이
    • 내분비종양
    • 림프종
    • 기타

제8장 핵의학 시장 : 시술 건수 평가

  • 서론
  • 진단용 시술
  • 치료용 시술

제9장 핵의학 시장 : 최종사용자별

  • 서론
  • 병원
  • 영상센터
  • 학술 및 연구센터
  • 기타

제10장 핵의학 시장 : 지역별

  • 서론
  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 독일
    • 프랑스
    • 영국
    • 이탈리아
    • 스페인
    • 기타 유럽
  • 아시아태평양
    • 일본
    • 중국
    • 기타 아시아태평양
  • 기타 지역

제11장 경쟁 구도

  • 서론
  • 주요 기업이 채택한 전략
  • 시장 순위 분석
  • 주요 시장 기업의 매출 분석
  • 기업 평가 매트릭스
  • 신규 기업/중소기업용 경쟁 리더십 매핑
  • 경쟁 벤치마킹
  • 경쟁 시나리오

제12장 기업 개요

  • 주요 기업
    • GE HEALTHCARE
    • CARDINAL HEALTH
    • CURIUM
    • BAYER AG
    • LANTHEUS HOLDINGS, INC.
    • BRACCO IMAGING S.P.A.
    • PHARMALOGIC HOLDINGS CORP.
    • ECZACIBASI-MONROL NUCLEAR PRODUCTS
    • NTP RADIOISOTOPES SOC LTD.(A SUBSIDIARY OF SOUTH AFRICAN NUCLEAR ENERGY CORPORATION)
    • NORDION INC.
    • ADVANCED ACCELERATOR APPLICATIONS(A NOVARTIS COMPANY)
    • NORTHSTAR MEDICAL RADIOISOTOPES
    • ECKERT & ZIEGLER
    • ISOTOPE JSC
    • SIEMENS HEALTHINEERS
    • JUBILANT DRAXIMAGE, INC.(A SUBSIDIARY OF JUBILANT PHARMA)
  • 기타 기업
    • GLOBAL MEDICAL SOLUTIONS
    • SHINE TECHNOLOGIES, LLC
    • ISOTOPIA MOLECULAR IMAGING LTD.
    • BWXT MEDICAL LTD.
    • INSTITUTE OF ISOTOPES
    • CHINA ISOTOPE & RADIATION CORPORATION
    • YANTAI DONGCHENG PHARMACEUTICAL GROUP CO., LTD.
    • CYCLOPHARM
    • IRE ELIT

제13장 부록

LSH 23.05.24

The global nuclear medicine market is projected to reach USD 9.4 billion by 2028 from USD 5.5 billion in 2023, at a CAGR of 11.3% during the forecast period. Growth in the nuclear medicine market can primarily be attributed to factors such as the increasing prevalence of CVD, government initiatives to improve healthcare, rapid growth in the geriatric population and the growing adoption of PET and SPECT techniques. However, the short half-life of radiopharmaceuticals decreases their potential adoption, and are expected to challenge market growth to a certain extent.

Therapeutic segment is projected to grow at the highest CAGR during the forecast period

By type, the nuclear medicine market is segmented into diagnostic and therapeutic. The therapeutic segment is projected to grow at the highest CAGR during the forecast period. This can be attributed to growing applications of these isotopes in oncology, as these isotopes have minimal side effects as opposed to surgeries and chemotherapy.

Hospital end user segment is projected to account for the largest share of the nuclear medicine market

By end user, the nuclear medicine market is segmented into the nuclear medicine market is segmented into hospitals, imaging centers, academic & research centers and other end users, which include pharma/biotech companies and contract research organizations. In 2023, the hospital segment is projected to account for the largest share of the nuclear medicine market due to the growing focus on the automation & digitization of radiology patient workflows to improve the quality of patient care.

By region, North America is projected to account for the largest share of the nuclear medicine market

By region,North America accounted for the largest share of the nuclear medicine market in 2023. Factors such as rising prevalence of chronic diseases is expected to increase the number of diagnosis and treatment in this region, government funding, and company initiatives.

Breakdown of supply-side primary interviews: * By Company Type: Tier 1 - 64%, Tier 2 - 23%, and Tier 3 - 13% * By Designation: C-level - 35%, Director-level - 25%, and Others - 40% * By Region: North America - 42%, Europe - 21%, APAC -26%, Rest of the World -11%

Some of the prominent players operating in the nuclear medicine market include GE HealthCare (US),Cardinal Health (US), Curium (France),Bayer AG (Germany), Lantheus Holdings, Inc.(US), Bracco Imaging S.p.A. (Italy), PharmaLogic Holdings Corp. (US), EczacIbasI-Monrol Nuclear Products (Turkey), NTP Radioisotopes SOC Ltd (South Africa), Nordion Inc.(Canada), Advanced Accelerator Applications (France), NorthStar Medical Radioisotopes (US), Eckert & Ziegler (Germany), Isotope JSC (Russia), Siemens Healthineers (Germany), Jubilant DraxImage,Inc. (Canada).

Research Coverage

This report studies the nuclear medicine market based on type, application, procedure volume, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to four main regions and respective countries.

Key Benefits of Buying the Report

This report focuses on various levels of analysis-industry trends, market share of top players, and company profiles, which together form basic views and analyze the competitive landscape, and high-growth regions and their drivers, restraints, challenges, and opportunities. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the market and garner greater market shares.

This report provides insights into the following pointers:

  • Analysis of key drivers (increasing incidence and prevalence of target conditions, development of alpha-radioimmunotherapy-based targeted cancer treatments, initiatives to reduce the demand and supply gap of Mo-99), restraints (Short half-life of radiopharmaceuticals),opportunities (use of radiopharmaceuticals in neurological applications and high growth opportunities in emerging countries) and challenges (hospital budget cuts and high equipment costs) influencing the growth of nuclear medicine market.
  • Market Penetration: Comprehensive information on product portfolios offered by the top players in the global nuclear medicine market . The report analyzes this market by type, application, procedure volume, end user, and region
  • Product Development/Innovation: Detailed insights on upcoming trends and product launches in the global nuclear medicine market
  • Market Development: Comprehensive information on the lucrative emerging markets by type, application, procedure volume, end user, and region
  • Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global nuclear medicine market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players in the global nuclear medicine market

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED
  • 1.4 CURRENCY
  • 1.5 STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
  • 2.2 RESEARCH METHODOLOGY STEPS
    • FIGURE 1 RESEARCH METHODOLOGY: NUCLEAR MEDICINE MARKET
    • FIGURE 2 RESEARCH DESIGN
    • 2.2.1 SECONDARY DATA
      • 2.2.1.1 Secondary sources
    • 2.2.2 PRIMARY DATA
    • FIGURE 3 PRIMARY SOURCES
    • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
      • 2.2.2.1 Primary sources
      • 2.2.2.2 Key insights from primary sources
  • 2.3 MARKET SIZE ESTIMATION
    • FIGURE 5 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
    • FIGURE 6 REVENUE SHARE ANALYSIS: CARDINAL HEALTH
    • FIGURE 7 REVENUE ANALYSIS OF TOP FIVE COMPANIES: NUCLEAR MEDICINE MARKET (2022)
    • FIGURE 8 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NUCLEAR MEDICINE MARKET (2023-2028)
    • FIGURE 9 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
    • FIGURE 10 TOP-DOWN APPROACH
  • 2.4 MARKET DATA ESTIMATION AND TRIANGULATION
    • FIGURE 11 DATA TRIANGULATION METHODOLOGY
  • 2.5 STUDY ASSUMPTIONS
  • 2.6 RISK ASSESSMENT
    • TABLE 1 RISK ASSESSMENT: NUCLEAR MEDICINE MARKET
  • 2.7 STUDY LIMITATIONS
  • 2.8 NUCLEAR MEDICINE MARKET: RECESSION IMPACT

3 EXECUTIVE SUMMARY

    • FIGURE 12 NUCLEAR MEDICINE MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 13 NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 14 NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 15 NUCLEAR MEDICINE MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    • FIGURE 16 GEOGRAPHICAL SNAPSHOT OF NUCLEAR MEDICINE MARKET

4 PREMIUM INSIGHTS

  • 4.1 NUCLEAR MEDICINE MARKET OVERVIEW
    • FIGURE 17 HIGH PREVALENCE OF CANCER TO DRIVE MARKET GROWTH
  • 4.2 NORTH AMERICA: NUCLEAR MEDICINE MARKET, BY TYPE AND COUNTRY (2022)
    • FIGURE 18 US ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN NUCLEAR MEDICINE MARKET IN 2022
  • 4.3 NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC PROCEDURES, BY TYPE, 2023 VS. 2028
    • FIGURE 19 SPECT PROCEDURES TO CONTINUE TO DOMINATE DIAGNOSTIC PROCEDURES MARKET IN 2028
  • 4.4 NUCLEAR MEDICINE MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 20 CHINA TO WITNESS HIGHEST GROWTH IN NUCLEAR MEDICINE MARKET DURING FORECAST PERIOD
  • 4.5 NUCLEAR MEDICINE MARKET, BY APPLICATION
    • FIGURE 21 DIAGNOSTIC APPLICATIONS TO DOMINATE MARKET DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 22 NUCLEAR MEDICINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing incidence and prevalence of target conditions
      • 5.2.1.2 Development of alpha-radioimmunotherapy-based targeted cancer treatments
      • 5.2.1.3 Initiatives to reduce demand and supply gap of Mo-99
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Short half-life of radiopharmaceuticals
    • TABLE 2 PHYSICAL HALF-LIFE OF RADIOPHARMACEUTICALS
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Use of radiopharmaceuticals in neurological applications
      • 5.2.3.2 Growth opportunities in emerging economies
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Hospital budget cuts and high equipment costs
  • 5.3 VALUE CHAIN ANALYSIS
    • FIGURE 23 VALUE CHAIN ANALYSIS OF NUCLEAR MEDICINE MARKET
  • 5.4 ECOSYSTEM COVERAGE
  • 5.5 REGULATORY LANDSCAPE
    • 5.5.1 NORTH AMERICA
      • 5.5.1.1 US
      • 5.5.1.2 Canada
    • 5.5.2 EUROPEAN UNION
    • 5.5.3 ASIA PACIFIC
      • 5.5.3.1 Australia
      • 5.5.3.2 India
      • 5.5.3.3 China
    • 5.5.4 REST OF THE WORLD
      • 5.5.4.1 Turkey
      • 5.5.4.2 UAE
      • 5.5.4.3 South Africa
    • TABLE 3 NUCLEAR MEDICINE MARKET: REGULATORY LANDSCAPE
  • 5.6 PORTER'S FIVE FORCES ANALYSIS
    • 5.6.1 PORTER'S FIVE FORCES ANALYSIS: NUCLEAR MEDICINE MARKET
    • 5.6.2 DEGREE OF COMPETITION
    • 5.6.3 BARGAINING POWER OF SUPPLIERS
    • 5.6.4 BARGAINING POWER OF BUYERS
    • 5.6.5 THREAT FROM SUBSTITUTES
    • 5.6.6 THREAT FROM NEW ENTRANTS
  • 5.7 PIPELINE ANALYSIS
    • TABLE 4 PIPELINE ANALYSIS
  • 5.8 PATENT ANALYSIS
    • 5.8.1 PATENT PUBLICATION TRENDS FOR NUCLEAR MEDICINE MARKET
    • FIGURE 24 PATENT PUBLICATION TRENDS (JANUARY 2015-DECEMBER 2022)
    • FIGURE 25 TOP 9 COMPANIES WITH HIGHEST NUMBER OF PATENT APPLICATIONS IN LAST 10 YEARS
  • 5.9 INDUSTRY TRENDS
    • 5.9.1 INCREASING PARTNERSHIPS & COLLABORATIONS FOR INNOVATION
    • 5.9.2 GROWING DEMAND FOR PET RADIOPHARMACEUTICALS IN ONCOLOGY AND NEUROLOGY APPLICATIONS
    • 5.9.3 ADVANCES IN RESEARCH & DEVELOPMENT OF RADIOPHARMACEUTICALS IN EMERGING COUNTRIES
  • 5.10 PRICING ANALYSIS
    • TABLE 5 AVERAGE SELLING PRICE OF RADIOPHARMACEUTICALS, BY TYPE
    • TABLE 6 AVERAGE SELLING PRICE OF RADIOPHARMACEUTICALS IN EASTERN EUROPE, BY TYPE
    • TABLE 7 AVERAGE SELLING PRICE OF RADIOPHARMACEUTICALS IN MENAT REGION, BY TYPE
    • 5.10.1 AVERAGE SELLING PRICE TREND ANALYSIS
  • 5.11 KEY CONFERENCES & EVENTS IN 2023-2024
    • TABLE 8 NUCLEAR MEDICINE MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
  • 5.12 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS
    • TABLE 9 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS (%)
    • 5.12.2 BUYING CRITERIA
    • FIGURE 27 KEY BUYING CRITERIA FOR END USERS
    • TABLE 10 KEY BUYING CRITERIA FOR END USERS

6 NUCLEAR MEDICINE MARKET, BY TYPE

  • 6.1 INTRODUCTION
    • TABLE 11 NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • 6.2 DIAGNOSTIC NUCLEAR MEDICINE
    • TABLE 12 DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 13 DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 14 NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 15 EUROPE: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 16 ASIA PACIFIC: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • 6.2.1 SPECT RADIOPHARMACEUTICALS
    • TABLE 17 ALTERNATIVES TO COMMON TC-99M-BASED DIAGNOSTIC PROCEDURES DUE TO SEVERE TC-99M SHORTAGES
    • TABLE 18 SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 19 SPECT RADIOPHARMACEUTICALS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 20 NORTH AMERICA: SPECT RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 21 EUROPE: SPECT RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 22 ASIA PACIFIC: SPECT RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
      • 6.2.1.1 Tc-99m
        • 6.2.1.1.1 Tc-99m commanded largest share of SPECT radiopharmaceuticals market in 2022
    • TABLE 23 TC-99M MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 24 NORTH AMERICA: TC-99M MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 25 EUROPE: TC-99M MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 26 ASIA PACIFIC: TC-99M MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
      • 6.2.1.2 I-123
        • 6.2.1.2.1 Reduced exposure to radiation and lower risk of patients developing radiation-induced cancer to drive demand
    • TABLE 27 I-123 MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 28 NORTH AMERICA: I-123 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 29 EUROPE: I-123 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 30 ASIA PACIFIC: I-123 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
      • 6.2.1.3 Tl-201
        • 6.2.1.3.1 Potential substitute to Tc-99m to drive demand for TI-201
    • TABLE 31 TI-201 MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 32 NORTH AMERICA: TI-201 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 33 EUROPE: TI-201 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 34 ASIA PACIFIC: TI-201 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
      • 6.2.1.4 Ga-67
        • 6.2.1.4.1 Long half-life of Ga-67 to facilitate easy sales and distribution
    • TABLE 35 GA-67 MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 36 NORTH AMERICA: GA-67 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 37 EUROPE: GA-67 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 38 ASIA PACIFIC: GA-67 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
      • 6.2.1.5 Other SPECT isotopes
    • TABLE 39 OTHER SPECT ISOTOPES MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 40 NORTH AMERICA: OTHER SPECT ISOTOPES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 41 EUROPE: OTHER SPECT ISOTOPES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 42 ASIA PACIFIC: OTHER SPECT ISOTOPES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • 6.2.2 PET RADIOPHARMACEUTICALS
    • TABLE 43 PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 44 PET RADIOPHARMACEUTICALS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 45 NORTH AMERICA: PET RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 46 EUROPE: PET RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 47 ASIA PACIFIC: PET RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
      • 6.2.2.1 F-18
        • 6.2.2.1.1 F-18 to command largest share of PET radiopharmaceuticals market in 2022
    • TABLE 48 F-18 MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 49 NORTH AMERICA: F-18 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 50 EUROPE: F-18 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 51 ASIA PACIFIC: F-18 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
      • 6.2.2.2 Rb-82
        • 6.2.2.2.1 High accuracy offered by Rb-82 isotopes to support market growth
    • TABLE 52 RB-82 MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 53 NORTH AMERICA: RB-82 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 54 EUROPE: RB-82 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 55 ASIA PACIFIC: RB-82 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
      • 6.2.2.3 Other PET isotopes
    • TABLE 56 OTHER PET ISOTOPES MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 57 NORTH AMERICA: OTHER PET ISOTOPES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 58 EUROPE: OTHER PET ISOTOPES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 59 ASIA PACIFIC: OTHER PET ISOTOPES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.3 THERAPEUTIC NUCLEAR MEDICINE
    • TABLE 60 THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 61 THERAPEUTIC NUCLEAR MEDICINE MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 62 NORTH AMERICA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 63 EUROPE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 64 ASIA PACIFIC: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • 6.3.1 ALPHA EMITTERS
      • 6.3.1.1 Ra-223
        • 6.3.1.1.1 Easy production of Ra-223 to favor market growth
    • TABLE 65 RA-223 MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 66 NORTH AMERICA: RA-223 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 67 EUROPE: RA-223 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 68 ASIA PACIFIC: RA-223 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • 6.3.2 BETA EMITTERS
    • TABLE 69 BETA EMITTERS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 70 BETA EMITTERS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 71 NORTH AMERICA: BETA EMITTERS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 72 EUROPE: BETA EMITTERS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 73 ASIA PACIFIC: BETA EMITTERS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
      • 6.3.2.1 I-131
        • 6.3.2.1.1 I-131 to account for largest share of beta emitters market during forecast period
    • TABLE 74 I-131 MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 75 NORTH AMERICA: I-131 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 76 EUROPE: I-131 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 77 ASIA PACIFIC: I-131 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
      • 6.3.2.2 Y-90
        • 6.3.2.2.1 Increasing applications in treating hepatocellular carcinoma to propel growth
    • TABLE 78 Y-90 MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 79 NORTH AMERICA: Y-90 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 80 EUROPE: Y-90 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 81 ASIA PACIFIC: Y-90 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
      • 6.3.2.3 Sm-153
        • 6.3.2.3.1 Increasing incidence of bone metastasis to drive market
    • TABLE 82 SM-153 MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 83 NORTH AMERICA: SM-153 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 84 EUROPE: SM-153 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 85 ASIA PACIFIC: SM-153 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
      • 6.3.2.4 Lu-177
        • 6.3.2.4.1 Increasing incidence of neuroendocrine cancer to boost demand
    • TABLE 86 LU-177 MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 87 NORTH AMERICA: LU-177 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 88 EUROPE: LU-177 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 89 ASIA PACIFIC: LU-177 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
      • 6.3.2.5 Re-186
        • 6.3.2.5.1 Wide usage of Re-186 for bone pain relief to fuel growth
    • TABLE 90 RE-186 MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 91 NORTH AMERICA: RE-186 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 92 EUROPE: RE-186 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 93 ASIA PACIFIC: RE-186 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
      • 6.3.2.6 Other beta emitters
    • TABLE 94 OTHER BETA EMITTERS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 95 NORTH AMERICA: OTHER BETA EMITTERS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 96 EUROPE: OTHER BETA EMITTERS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 97 ASIA PACIFIC: OTHER BETA EMITTERS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • 6.3.3 BRACHYTHERAPY ISOTOPES
    • TABLE 98 BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 99 BRACHYTHERAPY ISOTOPES MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 100 NORTH AMERICA: BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 101 EUROPE: BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 102 ASIA PACIFIC: BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
      • 6.3.3.1 I-125
        • 6.3.3.1.1 I-125 to account for largest share of brachytherapy isotopes market
    • TABLE 103 I-125 MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 104 NORTH AMERICA: I-125 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 105 EUROPE: I-125 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 106 ASIA PACIFIC: I-125 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
      • 6.3.3.2 Ir-192
        • 6.3.3.2.1 Growing use of Ir-192 to treat prostate, skin, and oral cancer to boost growth
    • TABLE 107 IR-192 MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 108 NORTH AMERICA: IR-192 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 109 EUROPE: IR-192 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 110 ASIA PACIFIC: IR-192 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
      • 6.3.3.3 Pd-103
        • 6.3.3.3.1 Extensive use of Pd-103 in treatment of aggressive tumors to propel growth
    • TABLE 111 PD-103 MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 112 NORTH AMERICA: PD-103 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 113 EUROPE: PD-103 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 114 ASIA PACIFIC: PD-103 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
      • 6.3.3.4 Cs-131
        • 6.3.3.4.1 Growing use of Cs-131 in gynecological applications to aid growth
    • TABLE 115 CS-131 MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 116 NORTH AMERICA: CS-131 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 117 EUROPE: CS-131 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 118 ASIA PACIFIC: CS-131 MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
      • 6.3.3.5 Other brachytherapy isotopes
    • TABLE 119 OTHER BRACHYTHERAPY ISOTOPES MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 120 NORTH AMERICA: OTHER BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 121 EUROPE: OTHER BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 122 ASIA PACIFIC: OTHER BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)

7 NUCLEAR MEDICINE MARKET, BY APPLICATION

  • 7.1 INTRODUCTION
    • TABLE 123 NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • 7.2 DIAGNOSTIC APPLICATIONS
    • TABLE 124 NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 125 NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 126 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 127 EUROPE: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 128 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • 7.2.1 SPECT APPLICATIONS
    • TABLE 129 NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 130 NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 131 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 132 EUROPE: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 133 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
      • 7.2.1.1 Cardiology
        • 7.2.1.1.1 Rising incidence of CVDs to increase demand for cardiac diagnostic scans
    • TABLE 134 NUCLEAR MEDICINE MARKET FOR SPECT CARDIOLOGY APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 135 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR SPECT CARDIOLOGY APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 136 EUROPE: NUCLEAR MEDICINE MARKET FOR SPECT CARDIOLOGY APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 137 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR SPECT CARDIOLOGY APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
      • 7.2.1.2 Bone scans
        • 7.2.1.2.1 High precision of SPECT to boost adoption of bone scans
    • TABLE 138 NUCLEAR MEDICINE MARKET FOR SPECT BONE SCAN APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 139 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR SPECT BONE SCAN APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 140 EUROPE: NUCLEAR MEDICINE MARKET FOR SPECT BONE SCAN APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 141 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR SPECT BONE SCAN APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
      • 7.2.1.3 Thyroid
        • 7.2.1.3.1 Rising demand for combination SPECT/CT therapy to drive market growth
    • TABLE 142 NUCLEAR MEDICINE MARKET FOR SPECT THYROID APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 143 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR SPECT THYROID APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 144 EUROPE: NUCLEAR MEDICINE MARKET FOR SPECT THYROID APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 145 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR SPECT THYROID APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
      • 7.2.1.4 Pulmonary scans
        • 7.2.1.4.1 High accuracy and sensitivity of SPECT/CT pulmonary imaging to boost market
    • TABLE 146 NUCLEAR MEDICINE MARKET FOR SPECT PULMONARY SCAN APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 147 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR SPECT PULMONARY SCAN APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 148 EUROPE: NUCLEAR MEDICINE MARKET FOR SPECT PULMONARY SCAN APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 149 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR SPECT PULMONARY SCAN APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
      • 7.2.1.5 Other SPECT applications
    • TABLE 150 NUCLEAR MEDICINE MARKET FOR OTHER SPECT APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 151 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR OTHER SPECT APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 152 EUROPE: NUCLEAR MEDICINE MARKET FOR OTHER SPECT APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 153 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR OTHER SPECT APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • 7.2.2 PET APPLICATIONS
    • TABLE 154 NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 155 NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 156 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 157 EUROPE: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 158 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
      • 7.2.2.1 Oncology
        • 7.2.2.1.1 Increasing incidence of cancer to fuel market growth
    • TABLE 159 NUCLEAR MEDICINE MARKET FOR PET ONCOLOGY APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 160 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR PET ONCOLOGY APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 161 EUROPE: NUCLEAR MEDICINE MARKET FOR PET ONCOLOGY APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 162 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR PET ONCOLOGY APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
      • 7.2.2.2 Cardiology
        • 7.2.2.2.1 Growing preference for FDG in cardiac imaging to propel market
    • TABLE 163 NUCLEAR MEDICINE MARKET FOR PET CARDIOLOGY APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 164 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR PET CARDIOLOGY APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 165 EUROPE: NUCLEAR MEDICINE MARKET FOR PET CARDIOLOGY APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 166 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR PET CARDIOLOGY APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
      • 7.2.2.3 Neurology
        • 7.2.2.3.1 Increasing incidence of AD, epilepsy, and Parkinson's disease to increase adoption of PET imaging
    • TABLE 167 NUCLEAR MEDICINE MARKET FOR PET NEUROLOGY APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 168 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR PET NEUROLOGY APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 169 EUROPE: NUCLEAR MEDICINE MARKET FOR PET NEUROLOGY APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 170 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR PET NEUROLOGY APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
      • 7.2.2.4 Other PET applications
    • TABLE 171 NUCLEAR MEDICINE MARKET FOR OTHER PET APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 172 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR OTHER PET APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 173 EUROPE: NUCLEAR MEDICINE MARKET FOR OTHER PET APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 174 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR OTHER PET APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.3 THERAPEUTIC APPLICATIONS
    • TABLE 175 NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 176 NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 177 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 178 EUROPE: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 179 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • 7.3.1 THYROID INDICATIONS
      • 7.3.1.1 Increasing prevalence of thyroid disorders to boost market
    • TABLE 180 NUCLEAR MEDICINE MARKET FOR THYROID INDICATIONS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 181 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR THYROID INDICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 182 EUROPE: NUCLEAR MEDICINE MARKET FOR THYROID INDICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 183 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR THYROID INDICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • 7.3.2 BONE METASTASIS
      • 7.3.2.1 Introduction of novel therapies for bone metastasis to positively impact market growth
    • TABLE 184 NUCLEAR MEDICINE MARKET FOR BONE METASTASIS APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 185 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR BONE METASTASIS APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 186 EUROPE: NUCLEAR MEDICINE MARKET FOR BONE METASTASIS APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 187 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR BONE METASTASIS APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • 7.3.3 ENDOCRINE TUMORS
      • 7.3.3.1 US to dominate therapeutic nuclear medicine market for endocrine tumor applications
    • TABLE 188 NUCLEAR MEDICINE MARKET FOR ENDOCRINE TUMOR APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 189 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR ENDOCRINE TUMOR APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 190 EUROPE: NUCLEAR MEDICINE MARKET FOR ENDOCRINE TUMOR APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 191 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR ENDOCRINE TUMOR APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • 7.3.4 LYMPHOMA
      • 7.3.4.1 Development of new isotopes for treatment of lymphoma to present huge growth opportunities
    • TABLE 192 NUCLEAR MEDICINE MARKET FOR LYMPHOMA APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 193 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR LYMPHOMA APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 194 EUROPE: NUCLEAR MEDICINE MARKET FOR LYMPHOMA APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 195 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR LYMPHOMA APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • 7.3.5 OTHER THERAPEUTIC APPLICATIONS
    • TABLE 196 NUCLEAR MEDICINE MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 197 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 198 EUROPE: NUCLEAR MEDICINE MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 199 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)

8 NUCLEAR MEDICINE MARKET: PROCEDURAL VOLUME ASSESSMENT

  • 8.1 INTRODUCTION
    • TABLE 200 NUCLEAR MEDICINE MARKET, BY PROCEDURE, 2021-2028 (THOUSAND PROCEDURES)
    • TABLE 201 NUCLEAR MEDICINE MARKET, BY REGION, 2021-2028 (THOUSAND PROCEDURES)
  • 8.2 DIAGNOSTIC PROCEDURES
    • 8.2.1 HIGH PREVALENCE OF CANCER AND CARDIAC DISEASES TO DRIVE MARKET GROWTH
    • TABLE 202 NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC PROCEDURES, BY TYPE, 2021-2028 (THOUSAND PROCEDURES)
    • TABLE 203 NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC PROCEDURES, BY REGION, 2021-2028 (THOUSAND PROCEDURES)
  • 8.3 THERAPEUTIC PROCEDURES
    • 8.3.1 GROWING DEMAND FOR NON-INVASIVE METHODS TO SUPPORT MARKET GROWTH
    • TABLE 204 NUCLEAR MEDICINE MARKET FOR THERAPEUTIC PROCEDURES, BY TYPE, 2021-2028 (THOUSAND PROCEDURES)
    • TABLE 205 NUCLEAR MEDICINE MARKET FOR THERAPEUTIC PROCEDURES, BY REGION, 2021-2028 (THOUSAND PROCEDURES)

9 NUCLEAR MEDICINE MARKET, BY END USER

  • 9.1 INTRODUCTION
    • TABLE 206 NUCLEAR MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.2 HOSPITALS
    • 9.2.1 RISING TREND OF MODERNIZING IMAGING WORKFLOW TO DRIVE ADOPTION OF IMAGING SYSTEMS IN HOSPITALS
    • TABLE 207 NUCLEAR MEDICINE MARKET FOR HOSPITALS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 208 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR HOSPITALS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 209 EUROPE: NUCLEAR MEDICINE MARKET FOR HOSPITALS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 210 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR HOSPITALS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.3 IMAGING CENTERS
    • 9.3.1 GROWING NUMBER OF PRIVATE IMAGING CENTERS TO SUPPORT MARKET GROWTH
    • TABLE 211 NUCLEAR MEDICINE MARKET FOR IMAGING CENTERS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 212 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR IMAGING CENTERS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 213 EUROPE: NUCLEAR MEDICINE MARKET FOR IMAGING CENTERS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 214 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR IMAGING CENTERS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.4 ACADEMIC & RESEARCH CENTERS
    • 9.4.1 INCREASING COLLABORATIONS BETWEEN NUCLEAR IMAGING COMPANIES AND ACADEMIA TO PROPEL MARKET GROWTH
    • TABLE 215 NUCLEAR MEDICINE MARKET FOR ACADEMIC & RESEARCH CENTERS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 216 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR ACADEMIC & RESEARCH CENTERS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 217 EUROPE: NUCLEAR MEDICINE MARKET FOR ACADEMIC & RESEARCH CENTERS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 218 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR ACADEMIC & RESEARCH CENTERS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.5 OTHER END USERS
    • TABLE 219 NUCLEAR MEDICINE MARKET FOR OTHER END USERS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 220 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 221 EUROPE: NUCLEAR MEDICINE MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 222 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION)

10 NUCLEAR MEDICINE MARKET, BY REGION

  • 10.1 INTRODUCTION
    • TABLE 223 NUCLEAR MEDICINE MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 10.2 NORTH AMERICA
    • 10.2.1 NORTH AMERICA: IMPACT OF ECONOMIC RECESSION
    • FIGURE 28 NORTH AMERICA: NUCLEAR MEDICINE MARKET SNAPSHOT
    • TABLE 224 NORTH AMERICA: NUCLEAR MEDICINE MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 225 NORTH AMERICA: NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 226 NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 227 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 228 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 229 NORTH AMERICA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 230 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 231 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 232 NORTH AMERICA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 233 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 234 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 235 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 236 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 237 NORTH AMERICA: NUCLEAR MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.2.2 US
      • 10.2.2.1 US to dominate North American nuclear medicine market during forecast period
    • TABLE 238 US: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
    • TABLE 239 US: NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 240 US: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 241 US: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 242 US: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 243 US: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 244 US: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 245 US: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 246 US: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 247 US: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 248 US: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 249 US: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 250 US: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 251 US: NUCLEAR MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.2.3 CANADA
      • 10.2.3.1 Increasing initiatives for medical isotope development to support market growth
    • TABLE 252 CANADA: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
    • TABLE 253 CANADA: NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 254 CANADA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 255 CANADA: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 256 CANADA: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 257 CANADA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 258 CANADA: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 259 CANADA: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 260 CANADA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 261 CANADA: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 262 CANADA: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 263 CANADA: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 264 CANADA: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 265 CANADA: NUCLEAR MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.3 EUROPE
    • 10.3.1 EUROPE: IMPACT OF ECONOMIC RECESSION
    • TABLE 266 EUROPE: NUCLEAR MEDICINE MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 267 EUROPE: NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 268 EUROPE: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 269 EUROPE: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 270 EUROPE: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 271 EUROPE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 272 EUROPE: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 273 EUROPE: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 274 EUROPE: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 275 EUROPE: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 276 EUROPE: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 277 EUROPE: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 278 EUROPE: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 279 EUROPE: NUCLEAR MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.2 GERMANY
      • 10.3.2.1 Well-established healthcare system to drive market growth
    • TABLE 280 GERMANY: NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 281 GERMANY: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 282 GERMANY: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 283 GERMANY: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 284 GERMANY: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 285 GERMANY: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 286 GERMANY: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 287 GERMANY: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 288 GERMANY: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 289 GERMANY: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 290 GERMANY: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 291 GERMANY: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 292 GERMANY: NUCLEAR MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.3 FRANCE
      • 10.3.3.1 Rising incidence of diseases such as cancer, Alzheimer's, and Parkinson's disease to favor market growth
    • TABLE 293 FRANCE: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
    • TABLE 294 FRANCE: NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 295 FRANCE: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 296 FRANCE: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 297 FRANCE: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 298 FRANCE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 299 FRANCE: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 300 FRANCE: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 301 FRANCE: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 302 FRANCE: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 303 FRANCE: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 304 FRANCE: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 305 FRANCE: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 306 FRANCE: NUCLEAR MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.4 UK
      • 10.3.4.1 Growing demand for diagnostic imaging and growing awareness to drive market growth
    • TABLE 307 UK: NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 308 UK: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 309 UK: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 310 UK: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 311 UK: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 312 UK: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 313 UK: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 314 UK: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 315 UK: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 316 UK: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 317 UK: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 318 UK: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 319 UK: NUCLEAR MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.5 ITALY
      • 10.3.5.1 Rising geriatric population to support market growth
    • TABLE 320 ITALY: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
    • TABLE 321 ITALY: NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 322 ITALY: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 323 ITALY: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 324 ITALY: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 325 ITALY: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 326 ITALY: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 327 ITALY: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 328 ITALY: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 329 ITALY: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 330 ITALY: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 331 ITALY: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 332 ITALY: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 333 ITALY: NUCLEAR MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.6 SPAIN
      • 10.3.6.1 Increasing initiatives by SEMNIM to drive growth
    • TABLE 334 SPAIN: NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 335 SPAIN: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 336 SPAIN: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 337 SPAIN: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 338 SPAIN: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 339 SPAIN: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 340 SPAIN: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 341 SPAIN: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 342 SPAIN: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 343 SPAIN: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 344 SPAIN: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 345 SPAIN: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 346 SPAIN: NUCLEAR MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.7 REST OF EUROPE
    • TABLE 347 REST OF EUROPE: NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 348 REST OF EUROPE: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 349 REST OF EUROPE: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 350 REST OF EUROPE: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 351 REST OF EUROPE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 352 REST OF EUROPE: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 353 REST OF EUROPE: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 354 REST OF EUROPE: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 355 REST OF EUROPE: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 356 REST OF EUROPE: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 357 REST OF EUROPE: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 358 REST OF EUROPE: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 359 REST OF EUROPE: NUCLEAR MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.4 ASIA PACIFIC
    • 10.4.1 ASIA PACIFIC: IMPACT OF ECONOMIC RECESSION
    • FIGURE 29 ASIA PACIFIC: NUCLEAR MEDICINE MARKET SNAPSHOT (2022)
    • TABLE 360 ASIA PACIFIC: NUCLEAR MEDICINE MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 361 ASIA PACIFIC: NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 362 ASIA PACIFIC: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 363 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 364 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 365 ASIA PACIFIC: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 366 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 367 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 368 ASIA PACIFIC: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 369 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 370 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 371 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 372 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 373 ASIA PACIFIC: NUCLEAR MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.2 JAPAN
      • 10.4.2.1 Japan to dominate APAC nuclear medicine market
    • TABLE 374 JAPAN: NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 375 JAPAN: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 376 JAPAN: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 377 JAPAN: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 378 JAPAN: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 379 JAPAN: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 380 JAPAN: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 381 JAPAN: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 382 JAPAN: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 383 JAPAN: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 384 JAPAN: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 385 JAPAN: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 386 JAPAN: NUCLEAR MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.3 CHINA
      • 10.4.3.1 Increasing nuclear medicine infrastructure and growing prevalence of chronic diseases to augment market
    • TABLE 387 CHINA: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
    • TABLE 388 CHINA: NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 389 CHINA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 390 CHINA: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 391 CHINA: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 392 CHINA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 393 CHINA: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 394 CHINA: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 395 CHINA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 396 CHINA: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 397 CHINA: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 398 CHINA: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 399 CHINA: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 400 CHINA: NUCLEAR MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.4 REST OF ASIA PACIFIC
    • TABLE 401 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 402 REST OF ASIA PACIFIC: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 403 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 404 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 405 REST OF ASIA PACIFIC: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 406 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 407 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 408 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 409 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 410 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 411 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 412 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 413 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.5 REST OF THE WORLD
    • 10.5.1 REST OF THE WORLD: IMPACT OF ECONOMIC RECESSION
    • TABLE 414 REST OF THE WORLD: NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 415 REST OF THE WORLD: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 416 REST OF THE WORLD: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 417 REST OF THE WORLD: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 418 REST OF THE WORLD: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 419 REST OF THE WORLD: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 420 REST OF THE WORLD: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 421 REST OF THE WORLD: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 422 REST OF THE WORLD: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 423 REST OF THE WORLD: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 424 REST OF THE WORLD: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 425 REST OF THE WORLD: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 426 REST OF THE WORLD: NUCLEAR MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION)

11 COMPETITIVE LANDSCAPE

  • 11.1 INTRODUCTION
  • 11.2 STRATEGIES ADOPTED BY KEY PLAYERS
    • TABLE 427 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
  • 11.3 MARKET RANKING ANALYSIS
    • FIGURE 30 NUCLEAR MEDICINE MARKET: MARKET RANKING, 2022
  • 11.4 REVENUE ANALYSIS OF KEY MARKET PLAYERS
    • FIGURE 31 REVENUE SHARE ANALYSIS OF KEY PLAYERS
  • 11.5 COMPANY EVALUATION MATRIX
    • 11.5.1 STARS
    • 11.5.2 EMERGING LEADERS
    • 11.5.3 PERVASIVE PLAYERS
    • 11.5.4 PARTICIPANTS
    • FIGURE 32 NUCLEAR MEDICINE MARKET: COMPANY EVALUATION MATRIX (2021)
  • 11.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES
    • 11.6.1 PROGRESSIVE COMPANIES
    • 11.6.2 STARTING BLOCKS
    • 11.6.3 RESPONSIVE COMPANIES
    • 11.6.4 DYNAMIC COMPANIES
    • FIGURE 33 NUCLEAR MEDICINE MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES
  • 11.7 COMPETITIVE BENCHMARKING
    • 11.7.1 OVERALL FOOTPRINT OF KEY PLAYERS
    • TABLE 428 OVERALL FOOTPRINT OF KEY PLAYERS
    • TABLE 429 REGIONAL FOOTPRINT OF KEY PLAYERS
    • TABLE 430 TYPE FOOTPRINT OF KEY PLAYERS
  • 11.8 COMPETITIVE SCENARIO
    • 11.8.1 PRODUCT APPROVALS & ENHANCEMENTS
    • TABLE 431 KEY PRODUCT APPROVALS & ENHANCEMENTS
    • 11.8.2 DEALS
    • TABLE 432 KEY DEALS
    • 11.8.3 OTHER DEVELOPMENTS
    • TABLE 433 KEY OTHER DEVELOPMENTS

12 COMPANY PROFILES

  • 12.1 MAJOR PLAYERS
  • (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
    • 12.1.1 GE HEALTHCARE
    • TABLE 434 GE HEALTHCARE: BUSINESS OVERVIEW
    • FIGURE 34 GE HEALTHCARE: COMPANY SNAPSHOT (2022)
    • 12.1.2 CARDINAL HEALTH
    • TABLE 435 CARDINAL HEALTH: BUSINESS OVERVIEW
    • FIGURE 35 CARDINAL HEALTH: COMPANY SNAPSHOT (2022)
    • 12.1.3 CURIUM
    • TABLE 436 CURIUM: BUSINESS OVERVIEW
    • 12.1.4 BAYER AG
    • TABLE 437 BAYER AG: BUSINESS OVERVIEW
    • FIGURE 36 BAYER AG: COMPANY SNAPSHOT (2021)
    • 12.1.5 LANTHEUS HOLDINGS, INC.
    • TABLE 438 LANTHEUS HOLDINGS, INC.: BUSINESS OVERVIEW
    • FIGURE 37 LANTHEUS HOLDINGS, INC.: COMPANY SNAPSHOT (2021)
    • 12.1.6 BRACCO IMAGING S.P.A.
    • TABLE 439 BRACCO IMAGING S.P.A.: BUSINESS OVERVIEW
    • 12.1.7 PHARMALOGIC HOLDINGS CORP.
    • TABLE 440 PHARMALOGIC HOLDINGS CORP.: BUSINESS OVERVIEW
    • 12.1.8 ECZACIBASI-MONROL NUCLEAR PRODUCTS
    • TABLE 441 ECZACIBASI-MONROL NUCLEAR PRODUCTS: BUSINESS OVERVIEW
    • 12.1.9 NTP RADIOISOTOPES SOC LTD. (A SUBSIDIARY OF SOUTH AFRICAN NUCLEAR ENERGY CORPORATION)
    • TABLE 442 NTP RADIOISOTOPES SOC LTD.: BUSINESS OVERVIEW
    • 12.1.10 NORDION INC.
    • TABLE 443 NORDION INC.: BUSINESS OVERVIEW
    • 12.1.11 ADVANCED ACCELERATOR APPLICATIONS (A NOVARTIS COMPANY)
    • TABLE 444 ADVANCED ACCELERATOR APPLICATIONS: BUSINESS OVERVIEW
    • 12.1.12 NORTHSTAR MEDICAL RADIOISOTOPES
    • TABLE 445 NORTHSTAR MEDICAL RADIOISOTOPES: BUSINESS OVERVIEW
    • 12.1.13 ECKERT & ZIEGLER
    • TABLE 446 ECKERT & ZIEGLER: BUSINESS OVERVIEW
    • FIGURE 38 ECKERT & ZIEGLER: COMPANY SNAPSHOT (2021)
    • 12.1.14 ISOTOPE JSC
    • TABLE 447 JOINT STOCK COMPANY ISOTOPE (ISOTOPE JSC): BUSINESS OVERVIEW
    • 12.1.15 SIEMENS HEALTHINEERS
    • TABLE 448 SIEMENS HEALTHINEERS: BUSINESS OVERVIEW
    • FIGURE 39 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2022)
    • 12.1.16 JUBILANT DRAXIMAGE, INC. (A SUBSIDIARY OF JUBILANT PHARMA)
    • TABLE 449 JUBILANT DRAXIMAGE, INC.: BUSINESS OVERVIEW
  • 12.2 OTHER PLAYERS
    • 12.2.1 GLOBAL MEDICAL SOLUTIONS
    • 12.2.2 SHINE TECHNOLOGIES, LLC
    • 12.2.3 ISOTOPIA MOLECULAR IMAGING LTD.
    • 12.2.4 BWXT MEDICAL LTD.
    • 12.2.5 INSTITUTE OF ISOTOPES
    • 12.2.6 CHINA ISOTOPE & RADIATION CORPORATION
    • 12.2.7 YANTAI DONGCHENG PHARMACEUTICAL GROUP CO., LTD.
    • 12.2.8 CYCLOPHARM
    • 12.2.9 IRE ELIT
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제